Compare BTG & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTG | PTCT |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.3B |
| IPO Year | N/A | 2013 |
| Metric | BTG | PTCT |
|---|---|---|
| Price | $4.61 | $74.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 17 |
| Target Price | $6.00 | ★ $73.76 |
| AVG Volume (30 Days) | ★ 33.1M | 2.3M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.15 | ★ 8.94 |
| Revenue | ★ $2,507,049,000.00 | $1,779,150,000.00 |
| Revenue This Year | $68.08 | $128.32 |
| Revenue Next Year | $22.77 | N/A |
| P/E Ratio | $28.94 | ★ $8.58 |
| Revenue Growth | 30.97 | ★ 97.54 |
| 52 Week Low | $2.20 | $35.95 |
| 52 Week High | $5.94 | $87.50 |
| Indicator | BTG | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 47.85 |
| Support Level | $4.35 | $73.03 |
| Resistance Level | $4.74 | $78.77 |
| Average True Range (ATR) | 0.19 | 3.28 |
| MACD | 0.07 | -0.99 |
| Stochastic Oscillator | 86.42 | 11.61 |
B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into various markets. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.